HDAC9 and prostate cancer: For example, treating mice with SFN for 21 days at a daily dose of 7.5 μmol per animal resulted in a 40% reduction of implanted prostate cancer PC-3 that is associated with both a decrease in HDAC activity and an increase in global histone acetylation [33].